UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions

International journal of clinical practice (Esher), 2014-07, Vol.68 (7), p.900-918

2014

Volltextzugriff (PDF)

Cost-Effectiveness Of Nilotinib In Patients With Chronic Myeloid Leukaemia Eligible To Start The Treatment-Free Remission Phase In Italy

Value in health, 2015-11, Vol.18 (7), p.A457-A457

2015

Volltextzugriff (PDF)

Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective

Actas urologicas españolas, 2016-10, Vol.40 (8), p.513-522

2016

Volltextzugriff (PDF)

MSR31 Evidence Synthesis for Decision-Making: Is Meta-Analysis Always Required?

Value in health, 2022-12, Vol.25 (12), p.S355-S356

Snedecor, SJ

2022

Volltextzugriff (PDF)

Comparison of three Kinetic Models of HIV-1 Infection: Implications for Optimization of Treatment

Journal of theoretical biology, 2003-04, Vol.221 (4), p.519-541

SNEDECOR, SONYA J.

2003

Volltextzugriff (PDF)

EE501 Making R-Based Economic Models Even Shinier With Web-Based Interfaces

Value in health, 2022-12, Vol.25 (12), p.S154-S154

2022

Volltextzugriff (PDF)

Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression

Bulletin of mathematical biology, 2005-11, Vol.67 (6), p.1315-1332

Snedecor, Sonya J.

2005

Volltextzugriff (PDF)

Comparative Efficacy of Time to Virologic Suppression in Treatment-Naive HIV-1 Patients: A Network Meta-Analysis of Longitudinal Data

Value in health, 2016-11, Vol.19 (7), p.A380-A381

Snedecor, SJ

2016

Volltextzugriff (PDF)

PRM130 - Comparative Efficacy of Time to Virologic Suppression in Treatment-Naive HIV-1 Patients: A Network Meta-Analysis of Longitudinal Data

Value in health, 2016-11, Vol.19 (7), p.A380-A381

Snedecor, SJ

2016

Volltextzugriff (PDF)

Associations between signs and symptoms of dry eye disease: a systematic review

Clinical ophthalmology (Auckland, N.Z.), 2015-01, Vol.9 (default), p.1719-1730

2015

Volltextzugriff (PDF)

SA63 Communicating Complex Methodology Via Infographics: A MAIC Case Study

Value in health, 2022-12, Vol.25 (12), p.S495-S495

2022

Volltextzugriff (PDF)

EE344 Estimating the Utilization of and Expenditure on the Newly Approved Injectable Prep Required to Meet the "End the HIV Epidemic in the US” 2030 Goal of 90% Reduction in New HIV Infections

Value in health, 2022-07, Vol.25 (7), p.S402

2022

Volltextzugriff (PDF)

EE231 Calculating the Indirect Cost of Disease Recurrence and Subsequent Premature Mortality in Patients Diagnosed with Early-Stage Hepatocellular Carcinoma (HCC) in the United States (US)

Value in health, 2022-07, Vol.25 (7), p.S379

2022

Volltextzugriff (PDF)

EE106 Evaluation of Full Factorial and Latin Hypercube Sampling As Alternatives to Traditional Random Selection for Probabilistic Uncertainty Analyses

Value in health, 2022-07, Vol.25 (7), p.S355-S356

2022

Volltextzugriff (PDF)

Novel Indirect Comparison Methodology for Estimating Time-Dependent Response To Antimuscarinics for the Treatment of Oab

Value in health, 2014-11, Vol.17 (7), p.A584-A584

2014

Volltextzugriff (PDF)

MSR47 A Stepwise Approach for Assessing the Feasibility of Population-Adjusted Indirect Treatment Comparisons

Value in health, 2022-12, Vol.25 (12), p.S359-S359

2022

Volltextzugriff (PDF)

Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy

Pain practice, 2014-02, Vol.14 (2), p.167-184

2014

Volltextzugriff (PDF)

Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC)

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.294-294

2011

Volltextzugriff (PDF)

Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.9025-9025

2011

Volltextzugriff (PDF)

Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4581-4581

2011

Volltextzugriff (PDF)

Use of the Weibull Proportional Hazards Model to Estimate OS and PFS in 9 Blood Cancer Indications: Validation and Violation

Value in health, 2018-05, Vol.21, p.S222

2018

Volltextzugriff (PDF)

PRM71 - Use of the Weibull Proportional Hazards Model to Estimate OS and PFS in 9 Blood Cancer Indications: Validation and Violation

Value in health, 2018-05, Vol.21, p.S222-S222

2018

Volltextzugriff (PDF)

POSC64 Healthcare Costs and Resource Utilization in 1L Maintenance (1L MT) Treatment (Tx) of Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review

Value in health, 2022-01, Vol.25 (1), p.S98-S99

2022

Volltextzugriff (PDF)

Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6570-6570

2011

Volltextzugriff (PDF)

Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6572-6572

2011

Volltextzugriff (PDF)

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(155)

Publikationsform

Sprache

Englisch
(175)
Spanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(81)
Life Sciences & Biomedicine
(77)
Humans
(54)
Male
(28)
Animals
(26)
Biological And Medical Sciences
(23)
Female
(22)
Internal Medicine
(17)
Medical Sciences
(15)
Adult
(13)
Chickens
(12)
Drug Therapy
(11)
Human Immunodeficiency Virus
(11)
Hiv
(10)
Clinical Trials
(9)
Cost-Benefit Analysis
(9)
Fundamental And Applied Biological Sciences. Psychology
(9)
Hiv Infections - Drug Therapy
(9)
Meta-Analysis
(9)
Old Medline
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions

Cost-Effectiveness Of Nilotinib In Patients With Chronic Myeloid Leukaemia Eligible To Start The Treatment-Free Remission Phase In Italy

Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective

MSR31 Evidence Synthesis for Decision-Making: Is Meta-Analysis Always Required?

Comparison of three Kinetic Models of HIV-1 Infection: Implications for Optimization of Treatment

EE501 Making R-Based Economic Models Even Shinier With Web-Based Interfaces

Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression

Comparative Efficacy of Time to Virologic Suppression in Treatment-Naive HIV-1 Patients: A Network Meta-Analysis of Longitudinal Data

PRM130 - Comparative Efficacy of Time to Virologic Suppression in Treatment-Naive HIV-1 Patients: A Network Meta-Analysis of Longitudinal Data

Associations between signs and symptoms of dry eye disease: a systematic review

SA63 Communicating Complex Methodology Via Infographics: A MAIC Case Study

EE344 Estimating the Utilization of and Expenditure on the Newly Approved Injectable Prep Required to Meet the "End the HIV Epidemic in the US” 2030 Goal of 90% Reduction in New HIV Infections

EE231 Calculating the Indirect Cost of Disease Recurrence and Subsequent Premature Mortality in Patients Diagnosed with Early-Stage Hepatocellular Carcinoma (HCC) in the United States (US)

EE106 Evaluation of Full Factorial and Latin Hypercube Sampling As Alternatives to Traditional Random Selection for Probabilistic Uncertainty Analyses

Novel Indirect Comparison Methodology for Estimating Time-Dependent Response To Antimuscarinics for the Treatment of Oab

MSR47 A Stepwise Approach for Assessing the Feasibility of Population-Adjusted Indirect Treatment Comparisons

Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy

Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC)

Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC)

Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC)

Use of the Weibull Proportional Hazards Model to Estimate OS and PFS in 9 Blood Cancer Indications: Validation and Violation

PRM71 - Use of the Weibull Proportional Hazards Model to Estimate OS and PFS in 9 Blood Cancer Indications: Validation and Violation

POSC64 Healthcare Costs and Resource Utilization in 1L Maintenance (1L MT) Treatment (Tx) of Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review

Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP)

Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective

Suchergebnisse filtern